http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03024432-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_21c1c987c561d09f679d2b2ddbe61349 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dfae81468523c4a7e635145a1bfe2359 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_64f2ec10fa0b5d1d303ec269193ab1ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a7f54c55c0e4c47914268412af8f8ad |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 |
filingDate | 2002-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e55f33db549a5c25974188ba968207a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9106d9ca75845eed0465b366ea106c33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91eda742a63129c22609e1f31c5115ce |
publicationDate | 2003-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-03024432-A2 |
titleOfInvention | Device for transdermal administration for the treatment of urinary tract disorders |
abstract | This invention provides a device containing a compound of formula (I), wherein R represents a saturated or unsaturated C2-7 aliphatic acyl group optionally substituted by one or more halogen atoms, a hydroxy group, a Cl-6 alkoxy group, a carboxyl group, a C2-7 alkoxycarbonyl group, a 5 to 7-membered cycloalkyl group, a phenyl or naphthyl group; a C2-6 hydroxyalkyl group; an aliphatic acyloxyalkyl group having a C2-7 acyl group and a Cl-6 alkyl group; a Cl-6 alkyl group substituted by a Cl-6 alkoxy group, a carboxyl group, a C2-7 alkoxycarbonyl group, a C2-7 alkoxycarbonyl group substituted by a phenyl or naphthyl group, a carbamoyl group, a mono- or di-(Cl-6 alkyl)-substituted carbamoyl group or a cyano group; a benzoyl or naphthoyl group optionally substituted by one or more halogen atoms; a furoyl group or a pyridylcarbonyl group; and R1 represents a C l-6 alkyl group optionally substituted by one or more halogen atoms, a phenyl or a naphthyl group; the carbon atom marked '*' represents a carbon atom in (R)- configuration, (S)-configuration or a mixture thereof. The TTS is efficient in the treatment of urinary tract disorders, such as benign prostatic hypertrophy. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012057212-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2006038619-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-5813652-B2 |
priorityDate | 2001-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 229.